Baxter to Acquire 1 of the 16 Most Promising Private Companies in Medtech
Baxter Healthcare is set to acquire Cheetah Medical, a firm an analyst identified earlier this year as one of 16 disruptive private companies in medtech.
The transaction consists of an upfront cash consideration of $190 million, with potential for an additional $40 million based on clinical and commercial milestones. It is set to close in 4Q19.
Boston and Tel Aviv, Israel-based Cheetah Medical is a major provider of non-invasive hemodynamic monitoring technologies.
The addition of Cheetah Medical is expected to enhance Deerfield, IL-based Baxterâs presence in the specialized patient monitoring space with key technology used to guide fluid managementâa critical aspect of patient careâas too little or too much fluid can increase mortality and risk of complications.
Cheetah Medical said its Starling SV platform uses its Bioreactance technology to calculate stroke volume and additional hemodynamic parameters, providing a real-time assessment of heart function in critical care or surgical patients to ensure adequate blood perfusion and optimal fluid management.
The platform is completely noninvasive, holds broad applicability and is easy to use, and can provide dynamic assessments of fluid responsiveness to aid in physician treatment decision making.
In a release, David Ferguson, general manager, Medication Delivery, for Baxter, said, âthe robust capabilities and innovative monitoring technologies we will gain...
Source: MDDI - Category: Medical Devices Authors: Omar Ford Tags: IV Products Business Source Type: news
More News: Cardiology | Heart | Israel Health | Medical Devices | Mergers and Aquisitions | Middle East Health | Perfusion | Stroke